[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
Since early April 2016, seven more Chinese pharmaceutical manufacturers were added to the FDA import alert list, barring the companies from shipping any of their products to the US market. The total number of Chinese companies on the import list now hovers at nearly 50. GMP concerns and refusal to submit to inspections were listed as reasons.
[/membership]
INTERNATIONAL PHARMACEUTICAL QUALITY
Inside the Global Regulatory Dialogue
